Methotrexate and etanercept-induced primary cutaneous CD4 positive small/medium-sized pleomorphic T-cell lymphoma
An. bras. dermatol
; 91(3): 368-371, graf
Article
en En
| LILACS
| ID: lil-787311
Biblioteca responsable:
BR1.1
ABSTRACT
Abstract Immunosuppressive drugs and biological agents may represent a potential risk of lymphoma development in patients with rheumatoid arthritis. But most cases are diffuse, large B-cell lymphomas. Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma, a provisional entity in the 2005 WHO-EORTC classification of cutaneous lymphomas, is only described in a limited number of reports. To our knowledge, our case is a rare instance of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma, after associated treatment with methotrexate and etanercept, in a patient with moderate rheumatoid arthritis who had undergone an orchidectomy incorrectly.
Palabras clave
Texto completo:
1
Banco de datos:
LILACS
Asunto principal:
Neoplasias Cutáneas
/
Metotrexato
/
Linfoma Cutáneo de Células T
/
Etanercept
/
Inmunosupresores
Tipo de estudio:
Diagnostic_studies
Límite:
Humans
/
Male
Idioma:
En
Revista:
An. bras. dermatol
Asunto de la revista:
DERMATOLOGIA
Año:
2016
Tipo del documento:
Article
País de afiliación:
China